Developing vaccines to combat antibiotic-resistant infections and bioterrorism threats
Official title: Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases
Funded at Intravacc B.v. · NIH-11091390 · Data updated 2026-11-12
This study is working on new vaccines to help protect against infections from tough bacteria that don't respond to regular antibiotics, and it's aimed at making sure these vaccines are safe and effective for people when they need them most.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intravacc B.v. NIH-funded |
| Lab location | 1 site (Bilthoven, Netherlands) |
| Project start | September 21, 2022 |
| Project end | January 14, 2026 |
| Funding year | 2024 |
| Award (this year) | $2,674,055 |
| NIH project number | 75N93022C00058-P00004-9999-1 |
| Project ID | NIH-11091390 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of contracting antibiotic-resistant infections or those living in areas prone to infectious disease outbreaks.
✕Less likely to help
Patients who are not at risk for antibiotic-resistant infections or those with existing conditions that preclude vaccination may not benefit from this research.
What this research studies
This research focuses on creating advanced vaccine candidates aimed at preventing and treating infectious diseases, particularly those caused by antibiotic-resistant bacteria. The approach involves formulating and manufacturing vaccine components, conducting stability tests, and evaluating their effectiveness and safety through nonclinical studies in animal models. The ultimate goal is to prepare these vaccines for clinical trials, ensuring they are safe and effective for human use in response to outbreaks or bioterrorism events.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that protect patients from serious infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Previous research has shown success in developing vaccines for infectious diseases, indicating that this approach has potential for significant advancements.
Where this research is happening
-
Intravacc B.v.
Bilthoven, Netherlands Active
Researchers
- Principal investigator: Oosterhoff, Dinja — Intravacc B.v.
- Study coordinator: Oosterhoff, Dinja
Related research
Other NIH-funded projects on the same topics.
-
Developing a vaccine for a serious childhood illness caused by a virus.
This study is working on a new vaccine to help protect children from Acute Flaccid Myelitis (AFM), a serious condition linked to a virus, and it aims to eventually test the vaccine's safety and effectiveness in kids.
-
Creating a nasal vaccine to prevent gonorrhea
This study is working on a new nose spray vaccine to help prevent gonorrhea, a common sexually transmitted infection, and if it works well in tests, it could offer a simple way to protect people from getting this infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.